D
Design Therapeutics, Inc.
DSGN
$4.72
-$0.24-4.84%
D
Sell
4/17/2024Upgraded
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 4/17/2024 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.282 to -$0.2111, EBIT increased 19.66% from -$18.82M to -$15.12M, and operating cash flow increased 11.94% from -$14.53M to -$12.8M.
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 4/17/2024 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.282 to -$0.2111, EBIT increased 19.66% from -$18.82M to -$15.12M, and operating cash flow increased 11.94% from -$14.53M to -$12.8M.
E
Sell
3/10/2023Downgrade
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D- on 3/10/2023 due to a decline in the volatility index and total return index.
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D- on 3/10/2023 due to a decline in the volatility index and total return index.
D
Sell
2/23/2023Upgraded
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 2/23/2023 due to an increase in the valuation index.
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 2/23/2023 due to an increase in the valuation index.
E
Sell
2/8/2023Downgrade
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D- on 2/8/2023 due to a large decline in the total return index and volatility index.
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D- on 2/8/2023 due to a large decline in the total return index and volatility index.
D
Sell
12/6/2022Downgrade
Design Therapeutics, Inc. (DSGN) was downgraded to D- from D on 12/6/2022 due to a decline in the volatility index and solvency index. The quick ratio declined from 48.74 to 33.13.
Design Therapeutics, Inc. (DSGN) was downgraded to D- from D on 12/6/2022 due to a decline in the volatility index and solvency index. The quick ratio declined from 48.74 to 33.13.
D
Sell
8/29/2022Upgraded
Design Therapeutics, Inc. (DSGN) was upgraded to D from D- on 8/29/2022 due to an increase in the total return index and volatility index.
Design Therapeutics, Inc. (DSGN) was upgraded to D from D- on 8/29/2022 due to an increase in the total return index and volatility index.
D
Sell
5/31/2022Upgraded
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 5/31/2022 due to an increase in the total return index and volatility index.
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 5/31/2022 due to an increase in the total return index and volatility index.
E
Sell
5/13/2022Downgrade
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, valuation index and volatility index. The quick ratio declined from 72.72 to 67.76.
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, valuation index and volatility index. The quick ratio declined from 72.72 to 67.76.
D
Sell
5/5/2022Upgraded
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index and total return index.
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index and total return index.
E
Sell
4/20/2022Downgrade
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D- on 04/20/2022.
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D- on 04/20/2022.
D
Sell
3/31/2022Upgraded
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 3/31/2022 due to an increase in the total return index and volatility index.
Design Therapeutics, Inc. (DSGN) was upgraded to D- from E+ on 3/31/2022 due to an increase in the total return index and volatility index.
E
Sell
3/15/2022Downgrade
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D on 3/15/2022 due to a substantial decline in the efficiency index and growth index. Operating cash flow declined 13.02% from -$8.16M to -$9.23M, and total capital declined 2.42% from $395.31M to $385.76M.
Design Therapeutics, Inc. (DSGN) was downgraded to E+ from D on 3/15/2022 due to a substantial decline in the efficiency index and growth index. Operating cash flow declined 13.02% from -$8.16M to -$9.23M, and total capital declined 2.42% from $395.31M to $385.76M.
D
Sell
12/2/2021Upgraded
Design Therapeutics, Inc. (DSGN) was upgraded to D from D- on 12/2/2021 due to an increase in the volatility index, total return index and valuation index.
Design Therapeutics, Inc. (DSGN) was upgraded to D from D- on 12/2/2021 due to an increase in the volatility index, total return index and valuation index.
D
Sell
11/16/2021Downgrade
Design Therapeutics, Inc. (DSGN) was downgraded to D- from D on 11/16/2021 due to a decline in the growth index, total return index and efficiency index. Net income declined 48.22% from -$7.64M to -$11.32M, earnings per share declined from -$0.1386 to -$0.2052, and EBIT declined 47.48% from -$7.69M to -$11.34M.
Design Therapeutics, Inc. (DSGN) was downgraded to D- from D on 11/16/2021 due to a decline in the growth index, total return index and efficiency index. Net income declined 48.22% from -$7.64M to -$11.32M, earnings per share declined from -$0.1386 to -$0.2052, and EBIT declined 47.48% from -$7.69M to -$11.34M.
D
Sell
9/8/2021Upgraded
Design Therapeutics, Inc. (DSGN) was upgraded to D from E on 09/08/2021.
Design Therapeutics, Inc. (DSGN) was upgraded to D from E on 09/08/2021.
E
Sell
9/1/2021Upgraded
Design Therapeutics, Inc. (DSGN) was upgraded to E from E- on 09/01/2021.
Design Therapeutics, Inc. (DSGN) was upgraded to E from E- on 09/01/2021.
E
Sell
8/11/2021None
Design Therapeutics, Inc. (DSGN) was downgraded to E- from U on 08/11/2021.
Design Therapeutics, Inc. (DSGN) was downgraded to E- from U on 08/11/2021.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
